Date:10/21/2011

ling, manufacturing and marketing products; the Company's ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; the impact of distributor purchasing decisions on sales of the Company's products that are sold through distribution; the impact of competition, technological change, and veterinary hospital consolidation on the markets for the Company's products; changes or trends in veterinary medicine that affect the rate of use of the Company's products and services by veterinarians; the impact of the Company's inexperience in the human point-of-care market; the effects of operations outside the U.S., including  from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; the effects of interruptions to the Company's operations due to natural disasters or system failures; the loss of key employees; class action litigation due to stock price volatility; the effect on the Company's stock price if quarterly or annual operations results do not meet expectations of market analysts or investors in future periods; and potential exposures related to our worldwide provision for income taxes. A further description of these and other factors can be found in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, in the section captioned "Risk Factors."IDEXX Laboratories, Inc. and SubsidiariesConsolidated Statement of OperationsAmounts in thousands except per share data (Unaudited)Three Months EndedNine Months EndedSept. 30,Sept. 30,Sept. 30,Sept. 30,2011201020112010Revenue:Revenue$
300,954

$
269,628$
911,488

$
819,635Expenses and Income:Cost of revenue142,287

127,421423,863

385,783Gross profit158,667

142,207487,625

433,852Sales and marketing50,682

44,486152,641
'/>"/>

SOURCE IDEXX Laboratories, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine technology :

1. IDEXX Laboratories to Release 2011 Second Quarter Financial Results
2. NetMotion Wireless Tapped by IDEXX Laboratories to Provide Secure Mobile Access to Field Personnel
3. McAllister Software Systems, Inc. and IDEXX Laboratories, Inc. Announce Availability of the IDEXX VetLab(R) Station InterLink(TM) Connection to AVImark(R) 2010
4. IDEXX Laboratories to Release 2009 Fourth Quarter and Full-Year Financial Results
5. IDEXX Laboratories Announces Catalyst Dx(R) Placement Total for 2009 and Installed Base of SmartService(TM) Customers
6. Matrix Laboratories Completes Name Change to Mylan Laboratories
7. Unity Management Group Receives Large Purchase Order for their AIM Instrumentation Package From Barr Laboratories, Subdivision of TEVA Pharmaceuticals (NASDAQ: TEVA)
8. AIT Laboratories Launches New Tools for Prescription Compliance Monitoring
9. Roche to Expand Coagulation Testing Portfolio, Develop New Systems for Diagnostic Laboratories in US and Canada by 2014
10. Spaulding Clinical Announces New Strategic Partnership With Frontage Laboratories, Inc.
11. "Environmental Monitoring and Certification in Controlled Environments: Meeting Regulations and Achieving Effective Microbial Control for Pharmaceutical and Medical Device Manufacturers" - New White Paper from Microtest Laboratories